UK GLP-1 in May 2026: NHS Cohort 2 starts June, oral Wegovy live, Foundayo on the MHRA radar

The UK GLP-1 picture moved enough since our April buyer's guide that it's worth a focused May update. Three events stacked: NHS England integrated tirzepatide into the 2026/27 GP contract via new Quality and Outcomes Framework indicators effective April 1, oral Wegovy 25mg started shipping at private UK pharmacies in January, and the FDA approval of Foundayo (orforglipron) on April 1 puts the MHRA application on the same H2 2026 trajectory the EU is on. None of these flips the private-market reality that 95% of UK GLP-1 users still pay out of pocket, but they do change the routing arithmetic at the margin.

This is the May 2026 snapshot. NHS-side changes, private-side changes, what to do today.

NHS · Cohort 2 starts June 2026 (BMI 35-39.9)

NHS England's three-cohort phasing for tirzepatide weight management is the headline NHS news this year. The structure:

• Cohort 1 (April 2025 onward): tirzepatide via specialist weight management services for BMI 40+ with at least 4 of 5 qualifying comorbidities (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, established cardiovascular disease).
• Cohort 2 (June 2026 start): expansion to BMI 35-39.9 with the same comorbidity load. Primary-care prescribing path opens for the first time, mediated by GP practices that have signed up to the QOF indicators. Cohort 1 cohort continues running in parallel via specialist services.
• Cohort 3 (April 2027 start): broadens to BMI ≥40 with 3 (rather than 4) qualifying comorbidities. Larger cohort, more primary-care load.

The 2026/27 GP contract introduced two QOF indicators (announced March 2026, live April 1) covering tirzepatide initiation + ongoing wraparound care. Practices are not mandated to participate; uptake will vary by ICB. Practices that opt in get the QOF points (revenue) and the prescribing capacity; practices that opt out continue routing patients back to specialist services. NHS prescription charges apply unless the patient has a medical-exemption certificate.

Wraparound care (dietary advice, physical activity support) is required by both the MHRA product licence and NICE TA1026. The QOF structure builds the wraparound into the indicator scoring · a practice that initiates tirzepatide without documenting wraparound underperforms on the indicator. This is a real feature, not just compliance theatre · UK weight-management trials show wraparound improves both adherence and weight-loss outcomes.

Routing implication for May 2026: a UK reader whose BMI sits in the 35-39.9 band and who has 4+ qualifying comorbidities can plan for a June onwards conversation with their GP. Below that BMI threshold or with fewer comorbidities, the NHS path is closed for now (Cohort 3 in April 2027 will reach more readers). Private routes remain the cash-pay alternative · see the April buyer's guide for the full vendor breakdown.

Private market · oral Wegovy 25mg available, brand supply stable

The oral semaglutide 25mg (Wegovy oral · launched in the US late December 2025) started shipping at UK private pharmacies in January 2026. Private cash-pay pricing settled in the £125-£175/month range depending on pharmacy. Boots, Pharmacy2U, ASDA Online Doctor, and the established UK telehealth platforms (Voy, Numan, ZAVA) all offer it; the headline differentiator is needle-free vs the injectable Wegovy / Ozempic / Mounjaro lineup.

Brand injectable supply stayed stable through Q1 2026. Mounjaro (tirzepatide) supply in particular has been steady at all major UK private channels · MHRA-approved, no shortage events since the 2024 recovery. Wegovy injectable similarly stable but pricier (~£140-£190/mo) and less differentiated post-oral-launch.

Routing implication: for a UK private-pay reader who is needle-averse, oral Wegovy 25mg is the new answer. The efficacy is below injectable tirzepatide (-13.6% vs -22.5% at matching trial endpoints) but the convenience is real. For maximum efficacy, injectable tirzepatide via Voy, Numan, or Boots remains the routable answer.

Private market · Foundayo (orforglipron) MHRA pathway

Lilly received FDA approval for Foundayo (oral small-molecule GLP-1) on April 1, 2026 under the National Priority Voucher program · the fastest NME approval since 2002. The EU EMA application was filed concurrently; the MHRA application typically lands within 1-3 months of the EMA filing.

Realistic UK timeline: MHRA decision late 2026 or H1 2027, given the EMA pattern (CHMP opinion typically 12-15 months from filing) plus the MHRA's typical 1-2 month additional review window. Lilly's 2026 launch playbook in the US (Ro partnership for $149/mo cash pricing) is a template for what the UK private market is likely to look like in late 2026 / early 2027.

Routing implication: too early to plan around. For UK readers who specifically want an oral path today, oral Wegovy 25mg is the only available answer. For readers willing to wait, Foundayo is plausibly 6-12 months away from UK availability via private pharmacies.

What to do today (May 2026)

Three reader profiles, three answers.

Profile 1 · BMI 35+ with 4+ qualifying comorbidities, NHS-eligible

• June 2026 onward: book a GP appointment to discuss tirzepatide via the QOF Cohort 2 pathway. Confirm your practice has opted into the QOF indicator (call the practice or check with your local ICB). Wraparound care expectations: dietary + activity coaching as part of the prescribing process.
• Before June: if symptomatic and your specialist weight-management service has capacity, ask for referral via Cohort 1 criteria.
• Cost: NHS prescription charge per item unless exempt. Wraparound care is included in the QOF payment, no patient cost.

Profile 2 · Below NHS thresholds, willing to pay privately

• Cash-pay tirzepatide: maximum efficacy + injectable. £150-£250/month at the major private routes. Voy (scorecard), Numan (scorecard), Boots (scorecard) are routable; Pharmacy2U and ASDA Online Doctor are conditional · see the April buyer's guide for the rubric scoring.
• Cash-pay oral Wegovy 25mg: needle-free, ~£125-£175/month. Lower efficacy than injectable tirzepatide but the convenience is meaningful. Same major pharmacies offer it.
• Behavioural-program wrap: Second Nature offers a structured year-long programme + medication via partner pharmacy. Slower-burn fit for readers who want lifestyle integration alongside the Rx.

Profile 3 · Watching the horizon

• Foundayo (orforglipron): MHRA decision late 2026 / early 2027. Will reset the UK oral GLP-1 pricing floor. Wait if cost is the binding constraint and you don't need the medication today.
• Retatrutide: phase 3 TRIUMPH-3 cardiovascular outcomes reads out 2027; FDA filing late 2026. UK availability via MHRA likely 2028 at earliest. Wait if you're targeting > 25% weight reduction and can defer.

What we're watching for the next update

• Cohort 2 actual GP uptake · which ICBs lean in, which lean out. Geographic variation will be real.
• Private-side oral Wegovy adoption rate · early data suggests strong demand; pricing may shift if competition intensifies.
• Foundayo MHRA filing confirmation · public when Lilly announces the submission.
• Compounded GLP-1 in the UK · UK pharmacies don't compound at the US scale, but watch MHRA enforcement on any provider claiming "compounded" injectable tirzepatide as a cash-pay alternative.

We'll publish another UK update when the Cohort 2 launch lands (post-June) or when Foundayo filing is confirmed.

For the full UK private-vendor breakdown: /blog/uk-glp1-buyers-guide-2026. For the May 2026 cross-region regulatory snapshot: /blog/peptide-pulse-may-2026. For the methodology behind every routing call: /blog/11-signals-vendor-rubric.